Update in HIV lymphoma.
OBJECTIVE
Despite the control of HIV infection in industrialized nations, individuals infected with HIV remain at increased risk of malignancies. Lymphoma is the most common HIV-associated malignancy in these countries. This review summarizes progress from January 2005 to March 2006.


RESULTS
Investigators continue to demonstrate that HIV-associated non-Hodgkin's lymphoma remains a significant problem, even in the era of highly active antiretroviral therapy. The majority of work has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising, and rituximab an area of investigation. The latter improves complete response rates, but is associated with an increased incidence of infections. Biological insights have been gained into the spectrum of HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease, and include further work on virological co-infections.


CONCLUSIONS
The outcome for individuals infected with HIV and developing non-Hodgkin's lymphoma and Hodgkin's disease continues to improve as insights into the pathophysiology and treatment advance.
Noy
Ariela
A
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. noya@mskcc.org
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy* / Q000821:virology; D011379:Prognosis
D044966:Anti-Retroviral Agents